comparemela.com
Home
Live Updates
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023 -October 12, 2023 at 01:12 am EDT : comparemela.com
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023 -October 12, 2023 at 01:12 am EDT
EQS-News: Heidelberg Pharma AG
/ Key word: 9 Month figures
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
12.10.2023 /...
Related Keywords
Hungary
,
Germany
,
South Africa
,
Switzerland
,
Coted Ivoire
,
Poland
,
Pratteln
,
Switzerland General
,
Berlin
,
Memorial Sloan Kettering Cancer Center
,
New York
,
United States
,
Melbourne
,
Victoria
,
Australia
,
Redhill
,
Free State
,
Thailand
,
Frankfurt
,
Brandenburg
,
Neu Ulm
,
Bayern
,
Croatia
,
Huadong
,
Phichit
,
Zagreb
,
Grad
,
Ivory Coast
,
American
,
Australian
,
Walter Miller
,
Sylvia Wimmer
,
Jan Schmidt
,
Eli Lilly
,
Heidelberg Pharma
,
Guanylyl Cyclase
,
Access Program
,
Santhera Pharmaceuticals
,
Corporate Communications
,
Heidelberg Pharma Group
,
Investors Announcements
,
Safety Review Committee
,
Optimapharm Group
,
Consortium For Enhanced Sepsis Outcomes
,
Telix Pharmaceuticals
,
Nuvisan Group
,
Nuclear Defense
,
Nasdaq
,
Heidelberg Pharma Research Gmb
,
Redhill Biopharma Ltd
,
Good Laboratory Practice
,
American Association For Cancer Research
,
Frankfurt Stock Exchange
,
Mc Services
,
Merck Kga
,
Early Access Program
,
Merck Kgaa
,
Interim Management Statement
,
First Nine Months
,
Jan Schmidt Brand
,
Antibody Targeted Amanitin Conjugate
,
American Association
,
Cancer Research
,
Executive Board
,
Chief Financial
,
Emergence Therapeutics
,
Partner Takeda
,
Antibody Targeted Amanitin
,
Telix Pharmaceuticals Limited
,
Expanded Access Program
,
Early Access
,
Enhanced Sepsis
,
Joint Program Executive Office
,
Heidelberg Pharma Research Gmbh
,
Financial Reports
,
Executive Management
,
Markets
,
comparemela.com © 2020. All Rights Reserved.